A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]

PHASE3UnknownINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2013

Conditions
Diastolic Heart Failure
Interventions
DRUG

Placebo

Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.

DRUG

Udenafil (Zydena)

Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.

Trial Locations (2)

463-707

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

110-744

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Dong-A Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Seoul National University Bundang Hospital

OTHER

lead

Seoul National University Hospital

OTHER